Combination phentermine/topiramate for obesity treatment in primary care: a review.

Glen Xiong, Kishore M. Gadde

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5% weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalPostgraduate Medicine
Volume126
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Phentermine
Weight Loss
Primary Health Care
Obesity
Insurance Benefits
Combination Drug Therapy
Psychiatry
Comorbidity
Heart Rate
Weights and Measures
Therapeutics
topiramate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination phentermine/topiramate for obesity treatment in primary care : a review. / Xiong, Glen; Gadde, Kishore M.

In: Postgraduate Medicine, Vol. 126, No. 2, 2014, p. 110-116.

Research output: Contribution to journalArticle

Xiong, Glen ; Gadde, Kishore M. / Combination phentermine/topiramate for obesity treatment in primary care : a review. In: Postgraduate Medicine. 2014 ; Vol. 126, No. 2. pp. 110-116.
@article{c2aaba64a03340c69a4393156a2c919a,
title = "Combination phentermine/topiramate for obesity treatment in primary care: a review.",
abstract = "The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5{\%} weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.",
author = "Glen Xiong and Gadde, {Kishore M.}",
year = "2014",
doi = "10.3810/pgm.2014.03.2746",
language = "English (US)",
volume = "126",
pages = "110--116",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - Combination phentermine/topiramate for obesity treatment in primary care

T2 - a review.

AU - Xiong, Glen

AU - Gadde, Kishore M.

PY - 2014

Y1 - 2014

N2 - The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5% weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.

AB - The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5% weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.

UR - http://www.scopus.com/inward/record.url?scp=84900558759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900558759&partnerID=8YFLogxK

U2 - 10.3810/pgm.2014.03.2746

DO - 10.3810/pgm.2014.03.2746

M3 - Article

C2 - 24685974

AN - SCOPUS:84900558759

VL - 126

SP - 110

EP - 116

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -